

PATENT
674523-2005.1# 14
VT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Alan John Kingsman *et al.*
U.S. Appln. No. : 09/915,169
U.S. Filing Date : July 25, 2001
Title of Invention : RETROVIRAL VECTORS
Patent No. : 6,669,936 *BR*
Issued : December 30, 2003
Examiner : Dave T. Nguyen
Art Unit : 1632

745 Fifth Avenue
New York, NY 10151

FILED VIA EFS
ON AUGUST 6, 2008

REQUEST FOR CERTIFICATE OF CORRECTION

Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

It is requested that a Certificate of Correction be issued in the above-entitled patent in accordance with the accompanying form PTO 1050. Please make the following changes:

PATENT
674523-2005.1**IN THE CLAIMS:**

Column 13, Claim 9 line 43

9. A method for expressing a gene of interest comprising introducing a gene of interest into a cell by contacting said cell with the retroviral vector particle of "claim 2" --claim 3--.

Column 13, Claim 11 line 57

11. A retroviral vector production system for producing infection and transduction competent, lentivirus-based vector particle according to claim 2, which system comprises nucleic acid sequence(s) encoding the genome of the vector particle, gag, pol, and an envelope protein, or the genome of the vector particle, gag, "poi" --pol--, an envelope protein, and comprising one or more RRE-type sequences, wherein all functional lentiviral auxiliary proteins are absent from the retroviral particle.

Column 15, Claim 36 line 26

26. The method of "claim" --claim 30-- wherein the coexpressing is of: a first DNA construct which encodes the genome of the vector particles, a second DNA construct which encodes gag and pol proteins, and a third DNA construct which encodes the envelope protein.

Column 15, Claim 37 line 34

37. The method of claim 31 wherein the coexpressing is of: a first DNA construct which encodes the genome of the vector particles, a second DNA construct which encodes gag and "poi" --pol-- proteins, and a third DNA construct which encodes the envelope protein, wherein one of the DNA constructs optionally comprises one or more RRE-type sequences.

Column 15, Claim 39 line 40

39. The method of "claims 31" --claim 31-- wherein the coexpressing includes expressing a DNA construct which encodes gag and pol proteins independent of auxiliary genes.

Column 15, Claim 46 line 56

46. The method of "claim 29" --claim 43-- wherein the promoter is a non-retroviral promoter.

PATENT
674523-2005.1

Column 15, Claim 47 line 53

47. The method of "claim 30" --claim 44-- wherein the promoter is a non-retroviral promoter.

Column 15, Claim 48 line 60

48. The method of "claim 31" --claim 45-- wherein the promoter is a non-retroviral promoter.

Column 16, Claim 56 line 34

56. Isolated nucleic acid sequence(s) encoding the components of the infection and transduction competent, lentivirus-based, replication defective vector particle as claimed in claim 1 or 2 comprising construct(s) which encode the genome of the vector particle, gag and "poi" -- pol-- proteins, and an envelope protein, wherein all functional auxiliary gene products are absent from the retroviral vector particle.

Column 18, Claim 69 line 5

69. Isolated nucleic acid sequence(s) encoding the components of the infection and transduction competent, lentivirus-based vector particle of claim 2, consisting essentially of construct(s) which encode(s) the RNA genome of the vector particle, gag and pol proteins, and an envelope protein, wherein the construct(s) comprises one or more "RLRIE-type" --RRE-type-- sequences.

Column 18, Claim 75 line 30

75. The isolated nucleic acid sequence(s) according to "claim 57 or 67" --claim 57 or 69--, wherein all genes encoding lentiviral auxiliary gene products are absent from or disrupted in the sequence(s) and not functionally expressed in producer cells.

PATENT
674523-2005.1**REMARKS**

Since the errors to be corrected are in part Applicants' errors, enclosed is payment of \$100.00 for the fee as required under 37 C.F.R. § 1.20(a). A completed Form PTO 1050 is enclosed. The Commissioner is authorized to charge any additional fees or credit any overpayments to Deposit Account No. 50-0320.

Applicants note that the following errors are attributable to the Office:

- Column 13, Claim 9 line 43
- Column 13, Claim 11 line 57
- Column 15, Claim 36 line 26
- Column 15, Claim 37 line 34
- Column 16, Claim 56 line 34
- Column 18, Claim 69 line 5
- Column 18, Claim 75 line 30

Applicants draw attention to the Preliminary Amendment filed July 25, 2001 and the Amendment and Response to Office Action filed March 25, 2003 to support Applicants' assertion that the errors are indeed attributable to the Office.

Applicants also point out that the following error is of Applicants' mistake, but constitutes a typographical error:

- Column 15, Claim 39 line 40

The correction requires changing "claims" from plural form to singular form and does not constitute new matter or require reexamination.

Finally, Applicants assert that the following errors are of Applicants' mistakes but are of minor character:

- Column 15, Claim 46 line 56
- Column 15, Claim 47 line 58
- Column 15, Claim 48 line 60

In accordance with MPEP § 1481, the requested changes do not materially affect the scope or meaning of the patent, as the changes are being requested merely to perfect antecedent basis of the term "promoter" in claims 46, 47, and 48. Applicants submit that claims 46, 47, and 48 were fully evaluated by the Examiner and their patentability would not be altered by modifying their claim dependency. Thus, the correction would not constitute new matter or require reexamination.


PATENT
674523-2005.1

Accordingly, Applicants respectfully request that the Director issue a certificate of correction to correct the errors cited herein.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP

By:


Thomas J. Kowalski
Reg. No. 32,147
Anne-Marie C. Yvon
Reg. No. 52,390
Russell A. Garman
Reg. No. 62,419
Tel: (212) 588-0800
Fax: (212) 588-0500

Electronic Acknowledgement Receipt

EFS ID:	3741296
Application Number:	09915169
International Application Number:	
Confirmation Number:	8430
Title of Invention:	RETROVIRAL VECTORS
First Named Inventor/Applicant Name:	Alan John Kingsman
Customer Number:	20999
Filer:	Deborah Lynn Lu/Russell Garman
Filer Authorized By:	Deborah Lynn Lu
Attorney Docket Number:	674523-2005.1
Receipt Date:	06-AUG-2008
Filing Date:	25-JUL-2001
Time Stamp:	19:22:48
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$ 100
RAM confirmation Number	6029
Deposit Account	
Authorized User	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part / .zip	Pages (if appl.)
-----------------	----------------------	-----------	-------------------------------------	-------------------	------------------

1	Request for Certificate of Correction	00571923.PDF	285379 e0f1b9062c80f8eda9623bae0433d54 044ab068	no	7
Warnings:					
Information:					
2	Fee Worksheet (FTO-06)	fee-info.pdf	8128 0a78d22830dddc35e2b3b13c954758 41470c008	no	2
Warnings:					
Information:					
Total Files Size (in bytes):					293507
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					

PTO/SB/44 (09-07)

Approved for use through 08/31/2010. OMB 0651-0033

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

Page 1 of 2

PATENT NO. : 6,669,936 *B2*
APPLICATION NO. : 09/915,169
ISSUE DATE : December 30, 2003
INVENTOR(S) : Alan John Kingsman
Susan Mary Kingsman
Narry Kim
Kyriacos Mitrophanous

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

IN THE CLAIMS:

Column 13, Claim 9 line 43

9. A method for expressing a gene of interest comprising introducing a gene of interest into a cell by contacting said cell with the retroviral vector particle of "claim 2" --claim 3--.

Column 13, Claim 11 line 57

11. A retroviral vector production system for producing infection and transduction competent, lentivirus-based vector particle according to claim 2, which system comprises nucleic acid sequence(s) encoding the genome of the vector particle, gag, pol, and an envelope protein, or the genome of the vector particle, gag, "poi" --pol--, an envelope protein, and comprising one or more RRE-type sequences, wherein all functional lentiviral auxiliary proteins are absent from the retroviral particle.

Column 15, Claim 36 line 26

26. The method of "claim" --claim 30-- wherein the coexpressing is of: a first DNA construct which encodes the genome of the vector particles, a second DNA construct which encodes gag and pol proteins, and a third DNA construct which encodes the envelope protein.

Column 15, Claim 37 line 34

37. The method of claim 31 wherein the coexpressing is of: a first DNA construct which encodes the genome of the vector particles, a second DNA construct which encodes gag and "poi" --pol-- proteins, and a third DNA construct which encodes the envelope protein, wherein one of the DNA constructs optionally comprises one or more RRE-type sequences.

Column 15, Claim 39 line 40

39. The method of "claims 31" --claim 31-- wherein the coexpressing includes expressing a DNA construct which encodes gag and pol proteins independent of auxiliary genes.

Column 15, Claim 46 line 56

46. The method of "claim 29" --claim 43-- wherein the promoter is a non-retroviral promoter.

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

00571773

6669936 B2

272

PTO/SB/44 (09-07)

Approved for use through 08/31/2010. OMB 0651-0033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

Column 15, Claim 47 line 58

47. The method of "claim 30" --claim 44-- wherein the promoter is a non-retroviral promoter.

Column 15, Claim 48 line 60

48. The method of "claim 31" --claim 45-- wherein the promoter is a non-retroviral promoter.

Column 16, Claim 56 line 34

56. Isolated nucleic acid sequence(s) encoding the components of the infection and transduction competent, lentivirus-based, replication defective vector particle as claimed in claim 1 or 2 comprising construct(s) which encode the genome of the vector particle, gag and "pol" --pol-- proteins, and an envelope protein, wherein all functional auxiliary gene products are absent from the retroviral vector particle.

Column 18, Claim 69 line 5

69. Isolated nucleic acid sequence(s) encoding the components of the infection and transduction competent, lentivirus-based vector particle of claim 2, consisting essentially of construct(s) which encode(s) the RNA genome of the vector particle, gag and pol proteins, and an envelope protein, wherein the construct(s) comprises one or more "RLRIE-type" --RRE-type-- sequences.

Column 18, Claim 75 line 30

75. The isolated nucleic acid sequence(s) according to "claim 57 or 67" --claim 57 or 69--, wherein all genes encoding lentiviral auxiliary gene products are absent from or disrupted in the sequence(s) and not functionally expressed in producer cells.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Thomas J. Kowalski, Esq.
 Frommer Lawrence & Haug LLP
 745 Fifth Avenue
 New York, New York 10151

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

00571773